You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
CD24 Is a Genetic Modifier for Risk and Progression of Multiple Sclerosis
Qunmin Zhou, Kottil Rammohan, Shili Lin, Nikki Robinson, Ou Li, Xingluo Liu, Xue-feng Bai, Lijie Yin, Bruce Scarberry, Peishuang Du, Ming You, Kunliang Guan, Pan Zheng and Yang Liu
Proceedings of the National Academy of Sciences of the United States of America
Vol. 100, No. 25 (Dec. 9, 2003), pp. 15041-15046
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/3148557
Page Count: 6
You can always find the topics here!Topics: Genotypes, T lymphocytes, Alleles, Complementary DNA, CHO cells, Population control, P values, Disease risks, Polymerase chain reaction, Blood
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Multiple sclerosis (MS) is a chronic neurological disease of unknown etiology, but a genetic basis for the disease is undisputed. We have reported that CD24 is required for the pathogenicity of autoreactive T cells in experimental autoimmune encephalomyelitis, the mouse model of MS. Here we investigate the contribution of CD24 to MS by studying single-nucleotide polymorphism in the ORF among 242 MS patients and 207 population controls. This single-nucleotide polymorphism results in replacement of alanine (CD24a) with valine (CD24v) in the mature protein. We found that the CD24v/v renders a >2-fold increase in the relative risk of MS in the general population (P = 0.023). Among familial MS, the CD24v allele is preferentially transmitted into affected individuals (P = 0.017). Furthermore, 50% of CD24v/v patients with expanded disability status scale 6.0 reached the milestone in 5 years, whereas the CD24a/v (P = 0.00037) and CD24a/a (P = 0.0016) patients did so in 16 and 13 years, respectively. Moreover, our data suggest that the CD24v/v patients expressed higher levels of CD24 on peripheral blood T cells than did the CD24a/a patients. Transfection with CD24a and CD24v cDNA demonstrated that the CD24v allele can be expressed at higher efficiency than the CD24a alleles. Thus, CD24 polymorphism is a genetic modifier for susceptibility and progression of MS in the central Ohio cohort that we studied, perhaps by affecting the efficiency of CD24 expression on the cell surface.
Proceedings of the National Academy of Sciences of the United States of America © 2003 National Academy of Sciences